潜在首款!默沙东口服PCSK9抑制剂III期研究成功

药渡
11 Jun

来源:药渡撰文:Pharmadeep编辑:维他命2025年6月9日,默沙东宣布其口服PCSK9抑制剂enlicitide decanoate(MK-0616)治疗高胆固醇血症的两项关键III期研究达到了主要终点。这一成果标志着该药物有望成为全球首个口服型PCSK9抑制剂,为降低低密度脂蛋白胆固醇(LDL-C)提供了新的潜在治疗选择。图1. MK-0616 III期试验结果公布,来源:默沙东官方公告...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10